Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Uncovering tripartite motif-containing 22 (TRIM22) binding partners and their roles in inflammatory bowel disease.
FY 2015-16
Summary
Inflammatory bowel disease (IBD) killed 55,000 in 1990 and 51,000 in 2013. This chronic condition causes inflammation (sore, swollen tissue) of the gastrointestinal tract and affects 1.5 million in America and 2.2 million in Europe. IBD is causedby a combination of factors such as immunology, environment, and gut bacteria. These factors interact with each other in complex ways, with genetics playing an underlying role in susceptibility. Genetics are especially important in anextreme form of the disease, very early onset IBD (VEOIBD). These children, diagnosed under age six, show symptoms distinct from adult IBD and are often difficult to treat. Current research aims to identify the genes involved in VEOIBD, describe how they cause disease, and propose new methods of therapy.Our lab recently identified defective copies of a gene called TRIM22 in three VEOIBD patients and showed how this gene affects pathways known to be involved in IBD. This gene holds instructions for creating the TRIM22 protein, whichnormally binds another protein that plays important roles in IBD. However, the defective versions of TRIM22 found in the three patients are unable to bind to this other important protein. This results in changes within the patients' cells whichlikely play a role in their severe symptoms. My research will focus on identifying other proteins that bind TRIM22, describe TRIM22's roles in these other pathways, and uncover any potential druggable targets within these networks. Abetter understanding of TRIM22 and its roles can improve genetic identification of VEOIBD while providing the potential for future drug therapies for typically unresponsive patients.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
349820
Name
Hossain Khalid
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Uncovering tripartite motif-containing 22 (TRIM22) binding partners and their roles in inflammatory bowel disease.
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cellular Pathways; Crohn'S Disease; Granulomatous Colitis; Inflammatory Bowel Disease; Perianal Disease; Protein Binding Partners; Tripartite Motif Containing 22 (Trim22); Ulcerative Colitis; Very Early Onset Inflammatory Bowel Disease (Veoibd)
Abstract
Inflammatory bowel disease (IBD) killed 55,000 in 1990 and 51,000 in 2013. This chronic condition causes inflammation (sore, swollen tissue) of the gastrointestinal tract and affects 1.5 million in America and 2.2 million in Europe. IBD is causedby a combination of factors such as immunology, environment, and gut bacteria. These factors interact with each other in complex ways, with genetics playing an underlying role in susceptibility. Genetics are especially important in anextreme form of the disease, very early onset IBD (VEOIBD). These children, diagnosed under age six, show symptoms distinct from adult IBD and are often difficult to treat. Current research aims to identify the genes involved in VEOIBD, describe how they cause disease, and propose new methods of therapy.Our lab recently identified defective copies of a gene called TRIM22 in three VEOIBD patients and showed how this gene affects pathways known to be involved in IBD. This gene holds instructions for creating the TRIM22 protein, whichnormally binds another protein that plays important roles in IBD. However, the defective versions of TRIM22 found in the three patients are unable to bind to this other important protein. This results in changes within the patients' cells whichlikely play a role in their severe symptoms. My research will focus on identifying other proteins that bind TRIM22, describe TRIM22's roles in these other pathways, and uncover any potential druggable targets within these networks. Abetter understanding of TRIM22 and its roles can improve genetic identification of VEOIBD while providing the potential for future drug therapies for typically unresponsive patients.
Competitiondate
201512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Hossain, Khalid
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~